BRPI0813309A2 - Capsídeo, mistura de capsídeos, proteína quimérica, métodos para produzir o capsídeo, e para produzir a mistura de capsídeos, e, complexo de hemicianina de lapa e epítopo l2 de papilomavírus humano 16. - Google Patents

Capsídeo, mistura de capsídeos, proteína quimérica, métodos para produzir o capsídeo, e para produzir a mistura de capsídeos, e, complexo de hemicianina de lapa e epítopo l2 de papilomavírus humano 16.

Info

Publication number
BRPI0813309A2
BRPI0813309A2 BRPI0813309A BRPI0813309A2 BR PI0813309 A2 BRPI0813309 A2 BR PI0813309A2 BR PI0813309 A BRPI0813309 A BR PI0813309A BR PI0813309 A2 BRPI0813309 A2 BR PI0813309A2
Authority
BR
Brazil
Prior art keywords
capsid
mix
producing
epype
hemicyanin
Prior art date
Application number
Other languages
English (en)
Inventor
Kazunari Kondo
Tadahito Kanda
Original Assignee
Japan Health Science Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Health Science Found filed Critical Japan Health Science Found
Publication of BRPI0813309A2 publication Critical patent/BRPI0813309A2/pt
Publication of BRPI0813309B1 publication Critical patent/BRPI0813309B1/pt
Publication of BRPI0813309B8 publication Critical patent/BRPI0813309B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
BRPI0813309A 2007-06-26 2008-06-25 capsídeo, mistura de capsídeos e proteína quimérica BRPI0813309B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007167154 2007-06-26
JP2007-167154 2007-06-26
PCT/JP2008/061569 WO2009001867A1 (ja) 2007-06-26 2008-06-25 高リスク群ヒトパピローマウイルスに対する交差性中和抗体を誘導するワクチン抗原

Publications (3)

Publication Number Publication Date
BRPI0813309A2 true BRPI0813309A2 (pt) 2014-12-23
BRPI0813309B1 BRPI0813309B1 (pt) 2020-10-06
BRPI0813309B8 BRPI0813309B8 (pt) 2021-05-25

Family

ID=40185679

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813309A BRPI0813309B8 (pt) 2007-06-26 2008-06-25 capsídeo, mistura de capsídeos e proteína quimérica

Country Status (14)

Country Link
US (1) US9023364B2 (pt)
EP (1) EP2168977B1 (pt)
JP (1) JP5540329B2 (pt)
KR (2) KR20150090285A (pt)
CN (1) CN101835796A (pt)
AU (1) AU2008268014B2 (pt)
BR (1) BRPI0813309B8 (pt)
CA (1) CA2691745C (pt)
ES (1) ES2688474T3 (pt)
MX (1) MX2009014246A (pt)
MY (1) MY152175A (pt)
NZ (1) NZ582271A (pt)
RU (1) RU2471807C2 (pt)
WO (1) WO2009001867A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2199301A1 (en) 2008-12-19 2010-06-23 DKFZ Deutsches Krebsforschungszentrum Immunogenic polypeptides comprising a scaffold polypeptide and a L2 polypeptide or fragment thereof
EP2416798B1 (en) * 2009-04-10 2017-09-20 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
CA2768172A1 (en) 2009-06-25 2010-12-29 Glaxosmithkline Biologicals S.A. Novel compositions
SI2585477T1 (sl) * 2010-06-23 2019-03-29 Deutsches Krebsforschungszentrum Preurejene tt virusne molekule za uporabo v diagnozi, preprečevanje in zdravljenje raka in avtoimunosti
CN103582651A (zh) 2010-12-27 2014-02-12 公益财团法人日本健康科学振兴财团 识别人类乳突病毒(hpv)l2蛋白质的单克隆抗体及使用其的测定hpv中和抗体的效价的方法
EP2940133A4 (en) * 2012-12-25 2016-07-06 Chemo Sero Therapeut Res Inst VACCINE FOR HPV INFECTION AND / OR HEPATITIS B WITH CHIMERIC HPV / HBS PROTEIN AS AN ACTIVE SUBSTANCE
CN107188966B (zh) * 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途
CN114716560B (zh) * 2021-01-04 2024-02-02 中国医学科学院基础医学研究所 一种人乳头瘤病毒18型嵌合蛋白及其用途
CN114716562B (zh) * 2021-01-04 2023-11-10 中国医学科学院基础医学研究所 一种人乳头瘤病毒58型嵌合蛋白及其用途
CN114716561B (zh) * 2021-01-04 2024-03-12 中国医学科学院基础医学研究所 一种人乳头瘤病毒31型嵌合蛋白及其用途
CN115337388A (zh) * 2022-07-01 2022-11-15 南方医科大学 一种抗菌和预防hpv病毒的按需释放凝胶及其制备方法
CN115724950B (zh) * 2022-11-15 2023-10-03 怡道生物科技(苏州)有限公司 Hpv6型衣壳蛋白l1单克隆抗体、制备方法及应用
CN116199772B (zh) * 2022-11-16 2023-10-17 怡道生物科技(苏州)有限公司 Hpv31型衣壳蛋白l1单克隆抗体、制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2189882C (en) 1994-05-16 2005-09-20 Kathrin U. Jansen Papillomavirus vaccines
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
RU2229307C1 (ru) * 2002-10-22 2004-05-27 ООО "Фирма"БиоМедИнвест" Композиция рекомбинантных белков, способ получения такой композиции, фармацевтический набор реагентов для иммунотерапии и профилактической вакцинации опухолевых заболеваний аногенитальной сферы, способ иммунотерапии и профилактической вакцинации на его основе
WO2005097987A1 (ja) * 2004-04-09 2005-10-20 Japan Health Sciences Foundation 粘膜指向性ヒトパピローマウイルス群の感染予防ワクチン抗原
KR20080025171A (ko) 2005-06-21 2008-03-19 메드이뮨 백신즈 인코포레이티드 이종성 프로테아제를 발현시키기 위한 방법 및 조성물
JP4825958B2 (ja) * 2005-08-10 2011-11-30 財団法人ヒューマンサイエンス振興財団 高リスク群ヒトパピローマウイルスの中和抗体を誘導する抗原

Also Published As

Publication number Publication date
ES2688474T3 (es) 2018-11-02
US9023364B2 (en) 2015-05-05
EP2168977A4 (en) 2013-12-18
CN101835796A (zh) 2010-09-15
MX2009014246A (es) 2010-03-31
EP2168977A1 (en) 2010-03-31
AU2008268014B2 (en) 2013-10-31
KR20150090285A (ko) 2015-08-05
AU2008268014A1 (en) 2008-12-31
EP2168977B1 (en) 2018-08-08
BRPI0813309B8 (pt) 2021-05-25
CA2691745C (en) 2017-08-15
US20100183648A1 (en) 2010-07-22
NZ582271A (en) 2012-03-30
BRPI0813309B1 (pt) 2020-10-06
WO2009001867A1 (ja) 2008-12-31
JPWO2009001867A1 (ja) 2010-08-26
KR101624358B1 (ko) 2016-05-26
MY152175A (en) 2014-08-15
KR20100029216A (ko) 2010-03-16
JP5540329B2 (ja) 2014-07-02
CA2691745A1 (en) 2008-12-31
RU2471807C2 (ru) 2013-01-10
RU2009148037A (ru) 2011-06-27

Similar Documents

Publication Publication Date Title
BRPI0813309A2 (pt) Capsídeo, mistura de capsídeos, proteína quimérica, métodos para produzir o capsídeo, e para produzir a mistura de capsídeos, e, complexo de hemicianina de lapa e epítopo l2 de papilomavírus humano 16.
IL258718A (en) Human anti-il-23 antibodies,compositions, methods and uses
LTPA2017011I1 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
EP1912667A4 (en) CONCENTRATED PROTEIN LYOPHILISATES, ASSOCIATED METHODS AND USES THEREOF
BRPI0817923A2 (pt) Implemento para cuidado oral, e, método
IL184175A (en) Sulfonyl pyrrolidines, method for producing the same and their use as drugs
NO2017005I1 (no) Human pappilomavirus vaksine [type 6, 11, 16, 18, 31, 33, 45, 52, 58]
IL191759A (en) Ganaxolone formulations and methods for the making and use thereof
BRPI0717041A2 (pt) produto alimentÍcio gaseificado, e, mÉtodo para preparar o mesmo
IL180682A0 (en) N-hydroxamide derivatives, their preparation and use
BRPI0821276A2 (pt) Produto, e, uso do produto
BRPI0718192A2 (pt) Corantes dispersos, sua preparação e seu uso.
DK2051975T3 (da) Substituerede prolinamider, fremstilling deraf og anvendelse deraf som lægemiddel.
EG25359A (en) Disposable diaper.
BRPI0806589A2 (pt) Catalisador, sua preparação e uso.
IL187392A0 (en) Thiazole derivatives, their preparation and use
IL184314A0 (en) Substituted 4-phenyltetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
DK1768833T3 (da) Formlegeme, fremgangsmåde til dets fremstilling samt dets anvendelse
GB0420062D0 (en) Assay methods,materials and preparations
IL190519A0 (en) 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof
FI20055470L (fi) Menetelmä maitotuotteiden valmistamiseksi, näin saadut tuotteet ja niiden käyttö
NO344962B1 (no) Amorf cesiumaluminiumfluorklompleks, dets fremstilling og bruk
DK1753725T3 (da) Tetra-hydro-iso-quinolinsulfonamidderivater, fremstilling og terapeutisk anvendelse heraf.
SI2020410T1 (sl) Derivati pirido(2,3-d)pirimidina, njihova priprava, njihova terapevtska uporaba
DE602005002294D1 (de) Druckplattenmaterial, Druckplatte und Druckverfahren.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: JAPAN HEALTH SCIENCES FOUNDATION (JP)

B25A Requested transfer of rights approved

Owner name: JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES (JP)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2832 DE 15-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.